A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Condition(s):Relapsed/Refractory Multiple Myeloma (RRMM)Last Updated:February 29, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Relapsed/Refractory Multiple Myeloma (RRMM)Last Updated:February 29, 2024Recruiting
Condition(s):Refractory Multiple Myeloma; Relapsed Multiple MyelomaLast Updated:March 12, 2024Recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:June 27, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:June 1, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:May 19, 2023Not yet recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 7, 2024Not yet recruiting
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:June 22, 2023Not yet recruiting
Condition(s):Relapsed/ Refractory Multiple MyelomaLast Updated:August 9, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:May 15, 2023Recruiting
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 12, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.